# Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components

> **NCT00453297** · PHASE1 · TERMINATED · sponsor: **Bionovo** · enrollment: 32 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MF101

## Key facts

- **NCT ID:** NCT00453297
- **Lead sponsor:** Bionovo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2008-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453297, "Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00453297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*